Company Filing History:
4 out of 137 
1 out of 4 Years Active: 2011-2017
Title: Masahiro Nishibori: Innovator in Therapeutic Agents
Introduction
Masahiro Nishibori is a prominent inventor based in Okayama, Japan. He has made significant contributions to the field of medical science, particularly in the development of therapeutic agents for inflammatory diseases. With a total of 4 patents to his name, Nishibori's work is recognized for its potential impact on treatment methodologies.
Latest Patents
Nishibori's latest patents include a therapeutic agent and methods for treating systemic inflammatory response syndrome (SIRS) and diseases associated with neutrophil activation. His invention provides a neutrophil activation regulator that comprises a histidine-rich glycoprotein (HRG). This invention aims to treat SIRS and related inflammatory diseases effectively. Additionally, he has developed methods for predicting the severity of SIRS and the survival of subjects suffering from these conditions by determining the blood level of HRG. Another notable patent is a humanized anti-HMGB1 antibody, which specifically binds to a sequence of the HMGB1 protein. This antibody is designed for the treatment or prevention of various inflammatory diseases.
Career Highlights
Masahiro Nishibori has worked with esteemed institutions such as Okayama University and Evec Incorporated. His research and innovations have contributed to advancements in therapeutic strategies for inflammatory conditions. His expertise in the field has positioned him as a valuable asset in medical research.
Collaborations
Nishibori has collaborated with notable colleagues, including Shuji Mori and Hideo Takahashi. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in medical science.
Conclusion
Masahiro Nishibori's contributions to the field of therapeutic agents highlight his dedication to improving treatment options for inflammatory diseases. His innovative patents and collaborations reflect his commitment to advancing medical research and patient care.